利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.017 秒)

    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF
    1.
    发明申请
    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF 审中-公开

    公开(公告)号：US20160030565A1

    公开(公告)日：2016-02-04

    申请号：US14873566

    申请日：2015-10-02

    申请人： Photocure ASA

    发明人： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness ,  Per Harald Fuglerud

    IPC分类号： A61K41/00 ,  A61N5/06 ,  A61K31/221

    CPC分类号： A61K41/0061 ,  A61K31/221 ,  A61N5/0616 ,  A61N5/062 ,  A61N2005/0652 ,  A61N2005/0662 ,  A61N2005/0663

    摘要： The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).

    Method of photodynamic therapy (PDT) for bladder cancer
    3.
    发明授权
    Method of photodynamic therapy (PDT) for bladder cancer 有权

    公开(公告)号：US11235168B2

    公开(公告)日：2022-02-01

    申请号：US16063142

    申请日：2016-12-19

    申请人： PHOTOCURE ASA

    发明人： Kjetil Hestdal ,  Aslak Godal

    IPC分类号： A61N5/06 ,  A61K41/00 ,  A61B1/307

    摘要： This invention relates to a method of photodynamic therapy (PDT) for bladder cancer and its use as an adjuvant or neoadjuvant therapy in the treatment of bladder cancer. The invention provides a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of photodynamic therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient in need of such treatment and the inside of said bladder is exposed to blue light having a fluence rate of 1.5 to 12.5 mW/cm2.

    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF
    4.
    发明申请
    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF 审中-公开
    氨基酸及其衍生物的使用

    公开(公告)号：US20130090592A1

    公开(公告)日：2013-04-11

    申请号：US13648946

    申请日：2012-10-10

    申请人： Photocure ASA

    发明人： Hans Christian WULF ,  Aslak Godal ,  Jo Klaveness

    IPC分类号： A61K41/00 ,  A61N5/06

    CPC分类号： A61K41/0061 ,  A61K31/221 ,  A61N5/062

    摘要： The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side-effects of PDT are prevented or reduced by using (iii) or (iv) in combination with (i) and/or (ii).

    摘要翻译： 本发明提供了5-氨基乙酰丙酸（5-ALA）或5-ALA衍生物（例如酯）或其药学上可接受的盐的光敏剂在制备用于 光动力疗法（PDT），其中所述PDT包括：（a）向所述动物施用包含所述光敏剂的组合物; 和（b）光活化所述光敏剂，并且其中通过使用（i） - （iv）中的一种或多种来防止或减少所述PDT的副作用（例如疼痛和/或红斑）：（i）所述组合物包含 浓度小于10％wt（例如0.5至8％wt）的光敏剂，（ii）所述组合物在所述光活化前施用少于2小时（例如30分钟至90分钟），（iii）所述光活化是 用光通量小于50mW / cm2（例如5〜40mW / cm2）的光源进行，（iv）所述的光活化是在太阳光下进行的。 优选地，通过使用（iii）或（iv）与（i）和/或（ii）组合来防止或减少PDT的副作用。

    METHOD OF PHOTODYNAMIC THERAPY (PDT) FOR BLADDER CANCER
    5.
    发明申请
    METHOD OF PHOTODYNAMIC THERAPY (PDT) FOR BLADDER CANCER 审中-公开

    公开(公告)号：US20190022404A1

    公开(公告)日：2019-01-24

    申请号：US16063142

    申请日：2016-12-19

    申请人： PHOTOCURE ASA

    发明人： Kjetil Hestdal ,  Aslak Godal

    IPC分类号： A61N5/06 ,  A61K41/00

    摘要： This invention relates to a method of photodynamic therapy (PDT) for bladder cancer and its use as an adjuvant or neoadjuvant therapy in the treatment of bladder cancer. The invention provides a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of photodynamic therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient in need of such treatment and the inside of said bladder is exposed to blue light having a fluence rate of 1.5 to 12.5 mW/cm2

    Carboxylic acid ALA esters
    7.
    发明授权
    Carboxylic acid ALA esters 有权
    羧酸ALA酯

    公开(公告)号：US09249086B2

    公开(公告)日：2016-02-02

    申请号：US14419125

    申请日：2013-08-02

    申请人： Photocure ASA

    发明人： Jon Erik Brænden ,  Colin Barry Charnock ,  Aslak Godal ,  Jo Klaveness ,  Nils Olav Nilsen

    IPC分类号： C07C229/24 ,  A61K41/00 ,  C07C229/22

    CPC分类号： C07C229/24 ,  A61K41/0061 ,  C07C229/22

    摘要： The invention relates to new derivatives of 5-aminolevulinic acid (5-ALA) and their use as photosensitizing agents. In particular, it relates to compounds of general formula I and their pharmaceutically acceptable salts, to methods for preparing such compounds and their medical and cosmetic use, for example in methods of photodynamic therapy and diagnosis: wherein R1 represents a hydrogen atom or an optionally substituted alkyl or cycloalkyl group; R2, each of which may be the same or different, represents a hydrogen atom or an optionally substituted alkyl group; and X is a linking group.

    摘要翻译： 本发明涉及5-氨基乙酰丙酸（5-ALA）的新衍生物及其作为光敏剂的用途。 具体地说，本发明涉及通式Ⅰ化合物及其药学上可接受的盐，制备这些化合物的方法及其医疗和化妆品用途，例如在光动力学治疗和诊断方法中：其中R1表示氢原子或任选取代的 烷基或环烷基; R2各自可以相同或不同，表示氢原子或任选取代的烷基; X是连接基团。

    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF
    10.
    发明申请
    USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF 审中-公开
    氨基酸及其衍生物的使用

    公开(公告)号：US20150150972A1

    公开(公告)日：2015-06-04

    申请号：US14616278

    申请日：2015-02-06

    申请人： Photocure ASA

    发明人： Hans Christian Wulf ,  Aslak Godal ,  Jo Klaveness ,  Per Harald Fuglerud

    IPC分类号： A61K41/00 ,  A61N5/06

    CPC分类号： A61K41/0061 ,  A61K31/221 ,  A61N5/0616 ,  A61N5/062 ,  A61N2005/0652 ,  A61N2005/0662 ,  A61N2005/0663

    摘要： The invention provides the use of a photosensitiser which is a derivative (e.g. an ester) of 5-aminolevulinic acid (5-ALA), or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises:(a) administering to said animal a composition comprising said photosensitiser; and(b) photoactivating said photosensitiser,and side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm2 (e.g. 5 to 40 mW/cm2), (iv) said photoactivation is carried out with sunlight. Preferably, side effects of PDT are prevented or reduced by using (ii) or (iv) in combination with (i) and/or (ii).

    摘要翻译： 本发明提供了在制备用于光动力学治疗方法（PDT）的组合物中使用作为5-氨基乙酰丙酸（5-ALA）的衍生物（例如酯）或其药学上可接受的盐的光敏剂的用途 ），其中所述PDT包括：（a）向所述动物施用包含所述光敏剂的组合物; 和（b）光活化所述光敏剂，并且通过使用（i） - （iv）中的一种或多种来防止或减少所述PDT的副作用（例如疼痛和/或红斑）：（i）所述组合物包含所述光敏剂 浓度小于10％wt（例如0.5-8％wt），（ii）所述组合物在所述光活化前施用少于2小时（例如30分钟至90分钟），（iii）所述光活化被携带 用光通量小于50mW / cm 2（例如5至40mW / cm 2）的光源，（iv）所述光活化在阳光下进行。 优选地，通过使用（ii）或（iv）与（i）和/或（ii）组合来防止或减少PDT的副作用。